BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

President Joe Biden on Wednesday urged parents to get their children vaccinated after a key Centers for Disease Control and Prevention advisory panel endorsed the use of Pfizer's and BioNTech's Covid-19 vaccine for adolescents aged 12 to 15.

Biden urges parents to get kids vaccinated after CDC panel endorses Pfizer Covid vaccine

Flush with Covid-19 vaccine cash, BioNTech SE ( BNTX , Financial) has set its sights higher. The German biotech's goal is to become what CEO Ugur Sahin calls a "global immunotherapy powerhouse.

BioNTech Aims Higher After Success of Covid-19 Vaccine

A Centers for Disease Control and Prevention committee voted 14-0-1 in favor of recommending that Pfizer Inc.'s COVID-19 vaccine can be safely used in 12 to 15 year olds. The recommendation, made Wednesday by the CDC's Advisory Committee on Immunization Practices, follows a similar regulatory pathway as the original emergency-use authorization awarded in December.

CDC committee recommends that Pfizer's COVID-19 shot be used in 12 to 15 year olds

The endorsement now awaits final approval by CDC Director Dr. Rochelle Walensky, which is expected imminently.

CDC panel endorses Pfizer's Covid vaccine for use in adolescents, clearing way for shots to begin Thursday

According to Reuters, Samsung BioLogics Co Ltd and Pfizer Inc (NYSE: PFE) have denied reports claiming they were working together to produce the COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) in South Korea. The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer/BioNTech vaccine.

Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters

States could begin administering shots in adolescents on Thursday, pending an endorsement from the CDC's Advisory Committee on Immunization Practices.

Five things to know before CDC panel votes on Pfizer's vaccine for use in adolescents

A Bryan Garnier prognosticator increases her price target despite the recommendation chop.

BioNTech Is No Longer a Buy, Says Analyst

Parents are pleased, but the move won't change much for the drug companies from a financial perspective.

Pfizer and BioNTech's COVID-19 Vaccine Authorized by the FDA for Adolescents

Children aged 12 to 15 could be able to get a COVID-19 vaccine as early as Thursday, a US Food and Drug Administration (FDA) official said. The FDA expanded the authorization for Pfizer-BioNTech's COVID-19 shot to include 12- to 15-year-olds on Monday, after first approving it for people aged 16 and older in late 2020.

Children aged 12 to 15 could start getting Pfizer's COVID-19 vaccine as soon as Thursday, FDA official says

AstraZeneca

Johnson & Johnson

Moderna

Novavax

The government is having issues with giving away its excess supply.

How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers?

NEW YORK and MAINZ, GERMANY, May 11, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

US regulators have approved the Pfizer COVID-19 vaccine for use in children as young as 12.

US regulators authorise use of Pfizer COVID-19 vaccine for ages 12 to 15

The U.S. Food and Drug Administration on Monday approved the emergency use of Pfizer Inc. (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine in adolescents aged between 12 to 15 years. What Happened: The FDA said it has amended the emergency use authorization (EUA) originally issued in December last year for administration of the vaccine in individuals 16 years of age and older.

Pfizer-BioNTech COVID-19 Vaccine Gets FDA Emergency Approval For Age Group 12-15

NIH Director Dr. Francis Collins says the FDA's emergency use authorization of Pfizer and BioNTech's Covid vaccine for kids ages 12 to 15 is “a big deal.”

‘It's a big deal' for America's push to reopen, says NIH Director on Pfizer vaccine approval for adolescents

The U.S. Food and Drug Administration has expanded the emergency use authorization for the Pfizer-BioNTech Covid-19 vaccine to include kids 12 to15 years old. That expands the Dec. 11, 2020 use authorization from individuals 16 years of age and older. It's the same dosage. It means a much bigger swathe of the U.S. population can...

FDA Authorizes Pfizer Covid Vaccine For Kids 12 To 15 Years Old

Anyone 12 years old or older will be able to get the jab.

FDA Expands Pfizer Coronavirus Vaccine Authorization For Adolescents

Americans aged 12 and up are now allowed to obtain the COVID-19 shot.

FDA authorizes Pfizer vaccine for children aged 12-15

FDA OKs use of Pfizer-BioNTech COVID-19 vaccine in kids ages 12 to 15

Teenagers in the US are now eligible for a leading coronavirus vaccine, as US regulators on Monday expanded the OK for Pfizer-BioNTech's COVID-19 shot to include 12- to 15-year-olds.  The two-dose vaccine was OK'd last December for anyone 16 years old and up. US health officials said they are prepared to soon start giving the shot to teenagers.

The US just authorized Pfizer-BioNTech's coronavirus vaccine for teenagers, making it the first COVID-19 shot OK'd for 12- to 15-year-olds

The FDA granting use of the shot in younger age groups will allow middle school-aged students to get vaccinated before school starts this fall.

FDA permits use of the Pfizer-BioNTech Covid vaccine in kids ages 12 to 15

BioNTech SE (BNTX) CEO Ugur Sahin on Q1 2021 Results - Earnings Call Transcript

The European Union hasn't made any new orders for AstraZeneca's COVID-19 vaccine beyond June, when the contract ends, said European internal market commissioner Thierry Breton.

EU won't renew AstraZeneca COVID-19 vaccine; Pfizer shot will take precedence

Studies published last week had shown the Pfizer-BioNTech shot to be highly effective against the more infectious emerging variant of the coronavirus.

BioNTech: Covid-19 Vaccine Does Not Need Any Changes To Protect Against Variants

Shares of BioNTech surged as much as 8% on Monday after the German-based company reported first quarter earnings that surpassed analyst estimates. The company, which developed the COVID-19 vaccine being distributed by Pfizer, saw a more than 7,000% jump in revenue year-over-year, from about €27 million to €2 billion.

BioNTech soars after COVID-19 vaccine drives monster earnings beat and stronger guidance (BNTX)

BioNTech (NASDAQ: BNTX) said on Monday its COVID-19 vaccine that it developed jointly with the U.S. based Pfizer Inc. helped lift its revenue significantly in the first quarter. BioNTech's was the first Coronavirus vaccine that secured authorisation from regulators.

News for BioNTech SE Stock (BNTX)